BioCentury
ARTICLE | Clinical News

Atlantic begins rolling NDA submission for pouchitis candidate alicaforsen

May 12, 2017 3:56 AM UTC

Atlantic Healthcare plc (Saffron Walden, U.K.) began submission of a rolling NDA to FDA for alicaforsen (AP 1007) to treat pouchitis. The antisense inhibitor of intercellular adhesion molecule-1 (ICAM-1; CD54) is in a Phase III trial in the indication...